IDEX Corporation's (IEX) position in the market has seen both positive and negative developments recently. The company, which has a strong reputation in the bio-tech sector, is on many banks and investment groups' radar, including DekaBank Deutsche Girozentral, Sequoia Financial Advisors, and Regency Capital Management. Both Stifel and Mizuho Securities have adjusted their ratings for IDEX, with the former lowering the price target from $204 to $191 but maintaining a 'Buy' recommendation, whereas Mizuho holds to a 'Hold' rating with a target price at $170. Earnings expectations for Q3 and Q2 have generally been positive, but there have been concerns about the company not meeting sales expectations. IDEX has received an average recommendation of 'Moderate Buy' from the analysts. The company has been procuring shares back and has declared regular quarterly cash dividends. Yet, certain analysts regard IDEX as overpriced and there are investors who express concerns about the company's return on capital.
Idex Corporation IEX News Analytics from Tue, 24 Dec 2024 08:00:00 GMT to Thu, 23 Oct 2025 09:44:29 GMT -
Rating 2
- Innovation 0
- Information 2
- Rumor -3
